Natalie McClure, SVP, Product Development at Adamas Pharmaceuticals Inc (ADMS), sold 20,000 shares at $14.50 ($290K) on 2014-12-01, disclosed to the SEC on 2014-12-03.
Scheduled sale ($290k) by SVP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ADMS | SELL | 2015-05-07 | $35K | — | Filing → |
| ADMS | SELL | 2015-04-07 | $35K | — | Filing → |
| ADMS | SELL | 2015-03-09 | $34K | — | Filing → |